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CD34+ STEM CELL SELECTION AND CD3+ ADDBACK FOR PEDIATRIC PA-
TIENTS RECEIVING MATCHED UNRELATED ADULT DONOR (MUD) PE-
RIPHERAL BLOOD STEM CELL TRANSPLANTATION (PBSCT) IS
ASSOCIATED WITH RAPID MYELOID ENGRAFTMENT AND LOW RISK OF
BOTH POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER (PTLD)
AND GRADE 2-4 ACUTE GRAFT VERSUS HOST DISEASE (AGVHD)
Geyer, M.B.1, Jacobson, J.S.2, Fearon, N.1, Satwani, P.1, Bhatia, M.1,
George, D.1, Bradley, M.B.1, Garvin, J.H.1, Harrison, L.1, Morris, E.1,
Fanelli, C.1, Semidei-Pomales, M.3, Daniel-Johnson, J.A.3, Schwartz, J.3,
Baxter-Lowe, L.A.4, Cairo, M.S.1,3,5 1Morgan Stanley Children’s Hospital,
New York-Presbyterian Hospital, Columbia University, NY; 2Columbia
University,NewYork,NY; 3ColumbiaUniversity,NewYork,NY; 4Univer-
sity of California, San Francisco, CA; 5Columbia University, New York, NY
Background: Positive selection of CD34 stem cells is a method of
depletion of T cells responsible for severe aGVHD (Lang et al.,
Blood, 2003). CD34-selected haploidentical SCT in children with
leukemia and nonmalignant diseases is associated with sustained en-
graftment and low risk of aGVHD (Lang/Handgretinger, BMT,
2008). Myeloablative conditioning (MAC) followed by CD34-se-
lected MUD PBSCT with a CD3 dose of 5105/kg carries high
risk of chronic GVHD (Bunin et al., BMT, 2006). We sought to de-
termine engraftment, survival, immune reconstitution (IR) and fre-
quency of PTLD and GVHD in pediatric patients at risk of severe
aGVHD following CD34-selected MUD PBSCT.
Methods: The Isolex 300i (Nexell, Irvine, CA) immunomagnetic
cell selection system was used for CD34 selection with a goal of
achieving$5 x106 CD34/kg PBSC. T cells were added back to reach
a total CD3 dose of 1.0-2.6105/kg. Conditioning wasMAC in 57%
vs. reduced intensity (RIC) in 43%. GVHD prophylaxis consisted
only of tacrolimus. Supportive care was as we have previously de-
scribed (Bradley/Cairo, BMT, 2007).
Results: Fourteen pts, median f/u of 451 d, median age of 15.0 yrs
(10-23); 1:1 M:F, HLA match 29% 10/10, 36% 9/10, 26% 8/10,
64% malignant (56/44% poor/average risk). Cell selection resulted
in median CD34 recovery of 59% and 4.33 CD3 log depletion
(Table 1).
All 14 pts engrafted neutrophils (median day 14, range 9-27).
Of 12 evaluable pts, 10 (83%) engrafted platelets (median day
32, range 21-44). No pts developed PTLD. One pt (7%) devel-
oped CMV infection. Probabilities of grade II-IV aGVHD and
chronic GVHD were 14.3% (95% CI 0-31%) and 36.4% (1-
59%) respectively. Day 100 mortality was 7%. The probability
of 1-year OS was 84% (67-100%). Of 9 pts with acute leukemia,
3 (33%) died from progressive disease. CD3, CD4, CD8, CD19
and CD56 counts at day +180/365 were normal in 20/38%, 0/
13%, 40/63%, 70/100% and 100/100% of pts, respectively. En-
graftment, GVHD, fungal infection and IR did not differ with
respect to conditioning; MAC recipients had higher risk of viral
infection (p5 .02) and mortality (5/8 in MAC vs. 0/6 in RTC,
but p5 .09)
Conclusions: Rapid neutrophil engraftment, no PTLD, minimal
grade II-IV aGVHD and high day 100 and overall survival were ob-
served. Depletion of B and T cells during CD34 selection may be re-
sponsible for the relatively slow recovery of T cells post-transplant.
These results support the continued investigation of CD34-selected
MUD PBSCT in pediatric recipients.
Table 1. Stem cell selection data for patients undergoing
CD341-selected MUD PBSCT
Median RangePre-Selection CD341 x 106 total cells 438.79 239.75 - 886.41
Post-Selection CD341 x 106 total cells 299.57 131.81 - 521.94
CD341 Percent Recovery 58.88 42.93 - 85.58
Final Infused CD341 x 106/kg 5.06 2.02 - 13.30
Pre-Selection CD31 x 108/kg 4.74 2.30 - 20.69
Post-Selection CD31 x 105/kg 0.220 \0.001 - 2.450
CD31 Log Depletion 4.33 2.45 - *
CD31 Addback x 105/kg 1.003 0 - 2.170
Final Infused CD31 x 105/kg 1.500 0.093 - 2.600*Post-selection CD31 was below the threshold of detection for two grafts.242
ANALYSIS OF THE INCIDENCE AND CHARACTERISTICS OF VENOOCCLU-
SIVE DISEASE (VOD) OF THE LIVER IN PEDIATRIC HEMATOPOIETIC PRO-
GENITOR CELL TRANSPLANT (HPCT) PATIENTS WITH HEPARIN ALONE
VS. HEPARIN AND URSODIOL PROPHYLAXIS AT THE MEDICAL COLLEGE
OF WISCONSIN
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VOD is a serious and potentially life-threatening complication of
HPCT as a result of liver injury from the effect of chemotherapy
and/or radiation. The reported incidence rate in pediatric HPCT
patients varies widely from 5% to 40%. Previous studies have shown
the beneficial effects of post-transplant pharmacological therapies
such as ursodeoxyholic acid (ursodiol), heparin, and defibrotide at
preventing VOD. However, the combined effect of heparin and ur-
sodiol prophylaxis in preventing VOD in pediatric patients has yet to
be determined. This study evaluated retrospectively whether there
was a benefit of such combined therapy in pediatric HPCT patients.
Our center adopted as standard practice for all HPCT patients the
initiation of low dose heparin at 4 units/kg/hour with the commence-
ment of conditioning for HPCT until day +28 post transplant. In
2003, we combined ursodiol 10 mg/kg TID to start with HPCT
conditioning and to continue until day + 100 post transplant with
low dose heparin through day + 28 for all pediatric HPCT patients.
We performed a retrospective chart review and compared the
characteristics and the incidence of VOD in patients who underwent
transplantation from 1996-2002 and received heparin alone com-
pared to 2003-2008 when the patients received the combination of
heparin and ursodiol prophylaxis. Patients were identified through
medical records with the ICD diagnosis of VOD. The medical re-
cords were reviewed and those patients who did not meet the Balti-
more criteria for the diagnosis of VODwere excluded. Only patients
who developed VOD with their first transplants were included.
The 100 day incidence of VODwas 0.0605 (SE 0.01618) in group
1 and 0.0227 (SE 0.01002) in group 2. The difference is 0.0377 (SE
0.0190) and based on a standard normal distribution with
a p5 0.0473. The day 100 survival in the VOD patients was 6 out
of 13 in group 1 and 3 out of 5 in group 2. In conclusion, low dose
heparin and ursodiol prophylaxis appears to be an effective strategy
in VOD prevention in pediatric patients. The combination appeared
to be more effective than heparin alone. However, this study is lim-
ited in that it is retrospective in nature. Future prospective trials need
to be performed in pediatric HPCT patients to further elucidate the
most efficacious and cost effective VOD prophylaxis, since currently
there is no consensus of what constitutes standard of care among pe-
diatric HPCT centers.
Group 1 Heparin Group 2 Heparin
(216) 1Ursodiol (220)Allogeneic 187 (86.5%) 160 (72.7%)
Autologous 29 (13.5%) 60 (27.3%)
Median Age 9 yrs 8 yrs
Male 123 (57%) 135 (62%)Non-malignant 34 (15.7%) 50 (22.8%)
Hematologic Malignancy 143 (66.2%) 109 (49.5%)
Non-hematologic Malignancy 39 (18.1%) 61 (27.7%)
# VOD 13 5243
OUTCOMES OF MATCHED RELATED DONOR HEMATOPOIETIC STEM CELL
TRANSPLANTATION IN PEDIATRIC PATIENTS WITH MYELODYSPLASTIC
SYNDROME
Parikh, S.H., Martin, P.L., Prasad, V.K., Szabolcs, P., Ciocci, G.,
Driscoll, T.A., Kurtzberg, J. Duke University Medical Center, Durham,
NC
Myelodysplastic syndromes (MDS) in children are associated with
significant morbidity and risk of leukemic transformation. Alloge-
neic hematopoietic stem cell transplantation is the only curative
therapy. The ideal allogeneic donor is an HLA-identical sibling or
